Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Buhl, ASK, Christensen, TD, Christensen, IJ, Nelausen, KM, Balslev, E, Knoop, AS, Brix, EH, Svensson, E, Glavicic, V, Luczak, A, Langkjer, ST, Linnet, S, Jakobsen, EH, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, PB 2018, 'Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study' Breast Cancer Research and Treatment, bind 172, nr. 2, s. 391-400. https://doi.org/10.1007/s10549-018-4918-4

APA

CBE

Buhl ASK, Christensen TD, Christensen IJ, Nelausen KM, Balslev E, Knoop AS, Brix EH, Svensson E, Glavicic V, Luczak A, Langkjer ST, Linnet S, Jakobsen EH, Bogovic J, Ejlertsen B, Rasmussen A, Hansen A, Knudsen S, Nielsen D, Jensen PB. 2018. Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study. Breast Cancer Research and Treatment. 172(2):391-400. https://doi.org/10.1007/s10549-018-4918-4

MLA

Vancouver

Author

Buhl, Anna Sofie Kappel ; Christensen, Troels Dreier ; Christensen, Ib Jarle ; Nelausen, Knud Mejer ; Balslev, Eva ; Knoop, Ann Søegaard ; Brix, Eva Harder ; Svensson, Else ; Glavicic, Vesna ; Luczak, Adam ; Langkjer, Sven Tyge ; Linnet, Søren ; Jakobsen, Erik Hugger ; Bogovic, Jurij ; Ejlertsen, Bent ; Rasmussen, Annie ; Hansen, Anker ; Knudsen, Steen ; Nielsen, Dorte ; Jensen, Peter Buhl. / Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study. I: Breast Cancer Research and Treatment. 2018 ; Bind 172, Nr. 2. s. 391-400.

Bibtex

@article{383cc0c692ff48de8f7b9473c568a335,
title = "Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study",
abstract = "PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining in vitro sensitivity and gene expression with clinical genetic information from > 3000 clinical tumor samples.METHODS: From a DBCG cohort, 140 consecutive patients were treated with epirubicin between May 1997 and November 2016. After patient informed consent, mRNA was isolated from archival formalin-fixed paraffin-embedded primary breast tumor tissue and analyzed using Affymetrix arrays. Using time to progression (TTP) as primary endpoint, the efficacy of epirubicin was analyzed according to DRP combined with clinicopathological data collected retrospectively from patients' medical records. Statistical analysis was done using Cox proportional hazards model stratified by treatment line.RESULTS: Median TTP was 9.3 months. The DRP was significantly associated to TTP (P = 0.03). The hazard ratio for DRP scores differing by 50 percentage points was 0.55 (95{\%} CI -0.93, one-sided). A 75{\%} DRP was associated with a median TTP of 13 months compared to 7 months following a 25{\%} DRP. Multivariate analysis showed that DRP was independent of age and number of metastases.CONCLUSION: The current study prospectively validates the predictive capability of DRP regarding epirubicin previously shown retrospectively allowing the patients predicted to be poor responders to choose more effective alternatives. Randomized prospective studies are needed to demonstrate if such an approach will lead to increased overall survival.",
author = "Buhl, {Anna Sofie Kappel} and Christensen, {Troels Dreier} and Christensen, {Ib Jarle} and Nelausen, {Knud Mejer} and Eva Balslev and Knoop, {Ann S{\o}egaard} and Brix, {Eva Harder} and Else Svensson and Vesna Glavicic and Adam Luczak and Langkjer, {Sven Tyge} and S{\o}ren Linnet and Jakobsen, {Erik Hugger} and Jurij Bogovic and Bent Ejlertsen and Annie Rasmussen and Anker Hansen and Steen Knudsen and Dorte Nielsen and Jensen, {Peter Buhl}",
year = "2018",
doi = "10.1007/s10549-018-4918-4",
language = "English",
volume = "172",
pages = "391--400",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

RIS

TY - JOUR

T1 - Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort

T2 - a retrospective-prospective blinded study

AU - Buhl, Anna Sofie Kappel

AU - Christensen, Troels Dreier

AU - Christensen, Ib Jarle

AU - Nelausen, Knud Mejer

AU - Balslev, Eva

AU - Knoop, Ann Søegaard

AU - Brix, Eva Harder

AU - Svensson, Else

AU - Glavicic, Vesna

AU - Luczak, Adam

AU - Langkjer, Sven Tyge

AU - Linnet, Søren

AU - Jakobsen, Erik Hugger

AU - Bogovic, Jurij

AU - Ejlertsen, Bent

AU - Rasmussen, Annie

AU - Hansen, Anker

AU - Knudsen, Steen

AU - Nielsen, Dorte

AU - Jensen, Peter Buhl

PY - 2018

Y1 - 2018

N2 - PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining in vitro sensitivity and gene expression with clinical genetic information from > 3000 clinical tumor samples.METHODS: From a DBCG cohort, 140 consecutive patients were treated with epirubicin between May 1997 and November 2016. After patient informed consent, mRNA was isolated from archival formalin-fixed paraffin-embedded primary breast tumor tissue and analyzed using Affymetrix arrays. Using time to progression (TTP) as primary endpoint, the efficacy of epirubicin was analyzed according to DRP combined with clinicopathological data collected retrospectively from patients' medical records. Statistical analysis was done using Cox proportional hazards model stratified by treatment line.RESULTS: Median TTP was 9.3 months. The DRP was significantly associated to TTP (P = 0.03). The hazard ratio for DRP scores differing by 50 percentage points was 0.55 (95% CI -0.93, one-sided). A 75% DRP was associated with a median TTP of 13 months compared to 7 months following a 25% DRP. Multivariate analysis showed that DRP was independent of age and number of metastases.CONCLUSION: The current study prospectively validates the predictive capability of DRP regarding epirubicin previously shown retrospectively allowing the patients predicted to be poor responders to choose more effective alternatives. Randomized prospective studies are needed to demonstrate if such an approach will lead to increased overall survival.

AB - PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining in vitro sensitivity and gene expression with clinical genetic information from > 3000 clinical tumor samples.METHODS: From a DBCG cohort, 140 consecutive patients were treated with epirubicin between May 1997 and November 2016. After patient informed consent, mRNA was isolated from archival formalin-fixed paraffin-embedded primary breast tumor tissue and analyzed using Affymetrix arrays. Using time to progression (TTP) as primary endpoint, the efficacy of epirubicin was analyzed according to DRP combined with clinicopathological data collected retrospectively from patients' medical records. Statistical analysis was done using Cox proportional hazards model stratified by treatment line.RESULTS: Median TTP was 9.3 months. The DRP was significantly associated to TTP (P = 0.03). The hazard ratio for DRP scores differing by 50 percentage points was 0.55 (95% CI -0.93, one-sided). A 75% DRP was associated with a median TTP of 13 months compared to 7 months following a 25% DRP. Multivariate analysis showed that DRP was independent of age and number of metastases.CONCLUSION: The current study prospectively validates the predictive capability of DRP regarding epirubicin previously shown retrospectively allowing the patients predicted to be poor responders to choose more effective alternatives. Randomized prospective studies are needed to demonstrate if such an approach will lead to increased overall survival.

U2 - 10.1007/s10549-018-4918-4

DO - 10.1007/s10549-018-4918-4

M3 - Journal article

VL - 172

SP - 391

EP - 400

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -

ID: 55423734